Bronfman E.L. Rothschild L.P. increased its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 1,108.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,112 shares of the biopharmaceutical company’s stock after acquiring an additional 1,020 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Emergent Biosolutions were worth $66,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Rehmann Capital Advisory Group lifted its stake in Emergent Biosolutions by 78.7% in the fourth quarter. Rehmann Capital Advisory Group now owns 452 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 199 shares during the period. D.A. Davidson & CO. increased its holdings in shares of Emergent Biosolutions by 7.6% in the fourth quarter. D.A. Davidson & CO. now owns 3,667 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 259 shares in the last quarter. Lido Advisors LLC increased its holdings in shares of Emergent Biosolutions by 6.1% in the fourth quarter. Lido Advisors LLC now owns 4,570 shares of the biopharmaceutical company’s stock worth $270,000 after acquiring an additional 263 shares in the last quarter. Pitcairn Co. increased its holdings in shares of Emergent Biosolutions by 3.9% in the fourth quarter. Pitcairn Co. now owns 7,051 shares of the biopharmaceutical company’s stock worth $418,000 after acquiring an additional 266 shares in the last quarter. Finally, American International Group Inc. increased its holdings in shares of Emergent Biosolutions by 1.0% in the fourth quarter. American International Group Inc. now owns 35,227 shares of the biopharmaceutical company’s stock worth $2,088,000 after acquiring an additional 350 shares in the last quarter. 84.63% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Daniel Abdun-Nabi sold 14,565 shares of Emergent Biosolutions stock in a transaction on Monday, March 4th. The stock was sold at an average price of $58.11, for a total value of $846,372.15. Following the transaction, the chief executive officer now owns 142,617 shares in the company, valued at approximately $8,287,473.87. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Fuad El-Hibri sold 27,725 shares of Emergent Biosolutions stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $58.83, for a total value of $1,631,061.75. Following the completion of the transaction, the chairman now owns 1,478,306 shares in the company, valued at approximately $86,968,741.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,132 shares of company stock valued at $3,411,113. Insiders own 13.40% of the company’s stock.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, February 21st. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.61 by $0.14. Emergent Biosolutions had a return on equity of 12.61% and a net margin of 8.02%. The firm had revenue of $270.70 million during the quarter, compared to analysts’ expectations of $269.05 million. During the same period in the prior year, the firm posted $0.74 earnings per share. The business’s quarterly revenue was up 39.7% compared to the same quarter last year. On average, research analysts predict that Emergent Biosolutions Inc will post 3.23 earnings per share for the current fiscal year.
Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Monday, April 8th. Wells Fargo & Co set a $68.00 price target on Emergent Biosolutions and gave the stock a “hold” rating in a report on Tuesday, April 2nd. Chardan Capital set a $71.00 price target on Emergent Biosolutions and gave the stock a “buy” rating in a report on Friday, February 22nd. ValuEngine downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Wednesday, March 20th. Finally, Cantor Fitzgerald set a $75.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a report on Friday, January 4th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $70.43.
ILLEGAL ACTIVITY NOTICE: “Bronfman E.L. Rothschild L.P. Buys 1,020 Shares of Emergent Biosolutions Inc (NYSE:EBS)” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/15/bronfman-e-l-rothschild-l-p-raises-stake-in-emergent-biosolutions-inc-ebs.html.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Further Reading: Why is the ROA ratio important?
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.